Background {#s1}
==========

Pulmonary nocardiosis is an unusual and severe opportunistic infection of the lungs caused by *Nocardia* spp.

It presents in immunocompromised patients with cavitary consolidation, including nodules, infiltration and reticular shadows.[@R1] Due to its uncharacteristic clinical manifestation and varied radiologic findings, its clinical diagnosis is complicated. As a fungal marker, β**-**d**-**glucan represents a non-invasive surveillance and diagnostic tool for invasive fungal infections. Limited reports have described the association between *Nocardia* infection and β**-**d**-**glucan.[@R2]

Case presentation {#s2}
=================

An 86-year-old woman, treated for 6 months with dexamethasone (4 mg/day) as palliative care due to progressive colorectal cancer, was admitted to the Department of Respiratory Medicine, Izumi City General Hospital. The patient presented with a month of intermittent cough, low-grade fever and chest pain. She never smoked. Previous medical history was remarkable for 5 years of diabetes mellitus. In addition, she was performed distal gastrectomy for gastric cancer 4 years ago and received an [excision](https://eow.alc.co.jp/search?q=excision&ref=awlj) of the [breast](https://eow.alc.co.jp/search?q=breast&ref=awlj) cancers 15 years ago. When the patient was first seen, a physical examination indicated the following: body temperature, 37.5°C; heart rate, 72 beats/min; blood pressure, 146/72 mm Hg; respiratory rate, 20/min and blood oxygen saturation level, 95% in room air. She was under low nutritional state with a body mass index of \<20.

Investigations {#s3}
==============

Chest radiography showed inhomogeneous shadows and large cavitary opacities in the bilateral upper fields ([figure 1A](#F1){ref-type="fig"}). CT showed large tumour-like shadows with ground-glass opacity in the bilateral upper lobes and the presence of large cavitary lesions \>5 cm in diameter with thin, irregular borders in the left upper lobe ([figure 1B](#F1){ref-type="fig"}).

![(A) Chest radiography on the initial visit, showing consolidations and large cavitary opacities in the bilateral upper field. (B and C) Chest CT showing large tumour-like shadows with ground-glass opacity in the bilateral upper lobes and a large cavity with thin, irregular borders in the left upper lobe.](bcr-2020-234738f01){#F1}

The patient's laboratory tests had the following features: a white cell count of 9.5 ×10^9^/L with 91.7% neutrophils, a haemoglobin level of 76 g/L and a C-reactive protein level of 14.8 mg/dL with no renal or liver function failure. The laboratory tests for HIV antibody, *Aspergillus* antigen, *Aspergillus* precipitating antibody, serum IgA antibody to glycopeptidolipid-core antigen and *Mycobacterium*-specific interferon-γ were negative. The tests for antineutrophil cytoplasmic antibodies were negative. β**-**d**-**glucan level (reference value \<20 pg/mL, Fungitec G test; Nissui Pharmaceutical, Tokyo, Japan) was elevated, reaching ≥300 pg/mL. We suspected opportunistic lung infections with bacteria, counting that she had been prescribed a high dose of methylprednisolone.

We considered invasive pulmonary aspergillosis to be the most likely cause of the high levels of β**-**d**-**glucan. However, her sputum of smear and culture was negative for *Aspergillus*. To make a diagnosis, bronchoscopy was performed from the right posterior and anterior bronchi. As performed the transbronchial biopsy from the right anterior and posterior segment, the pathological examination showed Gram-positive bacilli with microfilaments on Gram staining from the cavity wall tissue eaten by macrophages. There was the formation of fibrous granulomas with inflammatory cells composed neutrophils and lymphocytes in the alveolar cavity. We found no malignant findings. The smear of mucoid sputum obtained by brush cytology and bronchial washing revealed the similar Gram-positive bacilli ([figure 2](#F2){ref-type="fig"}). Smear specimen findings compatible with *Nocardia*, was not confirmed from culture. From 16S ribosomal RNA gene sequencing, a *Nocardia* species, specifically *Nocardia nova*, was identified. The culture of this secretion detected methicillin-sensitive *Staphylococcus aureus,* but not *Mycobacterium tuberculosis*. A sputum culture for *Mycobacteria avium* was positive only once during the hospitalisation period.

![Gram staining of the secretion from the cavity shows Gram-positive rods with branching microfilaments. *Nocardia nova* was identified by 16S ribosomal RNA gene sequencing.](bcr-2020-234738f02){#F2}

Differential diagnosis {#s4}
======================

Reported radiographic patterns for *Nocardia* infection include lobar or multilobar [consolidation](https://radiopaedia.org/articles/air-space-opacification-1?lang=us), infiltrative shadows, tumour shadows, cavities and bronchodilatational changes.[@R1] In our case, radiological abnormalities presented large tumour-like shadows and large cavitary lesions. For the cavitary lesions, we need to differentiate infectious or non-infectious diseases. First, we consider non-infectious diseases. Granulomatosis with polyangiitis (GPA) is an autoimmune disease that causes vasculitis in the small vessels. GPA presents central cavitation in up to 50% of cases and is more common in nodules larger than 2 cm.[@R4] Antineutrophil cytoplasmic antibodies were negative in the present case. Cavitary pulmonary cancer is most commonly (70%) caused by squamous cell carcinoma.[@R5] In our case, the pathological examination revealed no malignant findings. Second, we think about infectious diseases. Differential diagnoses from fungal infection and acid-fast bacteria are often the most important point, based on patient's immunologically deficient status. Nocardiosis is also often complicated by *M. avium* complex infection or chronic necrotising pulmonary aspergillosis.[@R7] In the present case, the high level of β**-**[d]{.smallcaps}**-**glucan hampered differentiation from pulmonary aspergillosis. Our patient was infected with *Nocardia*, *M. avium* and *S. aureus,* but not with *Aspergillus*.

Treatment {#s5}
=========

We diagnosed with pulmonary nocardiosis. Trimethoprim/sulfamethoxazole (TMP/SMX 1600 mg; 320 mg/day) and imipenem hydrate/cilastatin sodium (IPM/CS 1.5 g; 1.5 g/day) were prescribed as initial therapy. On the second day of the treatment, the patient suddenly developed an episode of tetanic convulsion. Brain MRI showed no abnormalities. The IPM/CS was considered the possible cause of seizures. The convulsive episode did not repeat after cessation of IPM/CS. Eighteen-day treatment with TMP/SMX alone improved cough, low-grade fever and chest pain. The inflammatory reaction, C-reactive protein, was normalised with white cell counts. Later, the patient was switched to oral minocycline (200 mg/day) monotherapy following an increase in the potassium serum levels as side effects of TMP/SMX.

Chest radiography on the 28th day of treatment showed an improvement in the shadows ([figure 3](#F3){ref-type="fig"}). Interestingly, the high levels of β**-**d**-**glucan observed at pretreatment decreased in parallel with the amelioration of the clinical features: the levels decreased from ≥300 pg/mL to 42.5 pg/mL after 45 days ([figure 4](#F4){ref-type="fig"}). The present patient showed no history of eating large amounts of mushrooms, receiving β-lactam antibiotics or immunoglobulin/albumin preparations along with haemodialysis, which are common sources of false-positive test findings for high β**-**d**-**glucan levels.[@R9]

![Chest radiography on the 28th day post-treatment showing improved consolidation shadows and cavities. The straight line in the left lower zone indicates left-sided pneumothorax.](bcr-2020-234738f03){#F3}

![Changes in the CRP and serum β-d-glucan levels. CRP, C-reactive protein; CS, cilastatin sodium; IPM, imipenem; SMX, sulfamethoxazole; TMP, trimethoprim.](bcr-2020-234738f04){#F4}

Outcome and follow-up {#s6}
=====================

The β**-**d**-**glucan levels decreased after the treatment, without antimycotic agents. We therefore believe that the increased β**-**d**-**glucan levels can be attributed to *Nocardia*. Unfortunately, the patient died from cancerous peritonitis 3 months after treatment initiation.

Discussion {#s7}
==========

*Nocardia* is a family of aerobic Gram-positive bacteria classified as actinomycetes, which are ubiquitous bacteria in the soil and aqueous environments. While actinomycetes are prokaryotes, like all bacteria, they are also micro-organisms with mycelium, and their infection patterns resemble those of fungi.[@R11] Nocardiosis is mainly recognised as an opportunistic infection primarily affecting immunodeficient patients who undergo long-term treatments with steroid hormones and immunosuppressants or who have a weakened immune system, such as patients with progressive cancer or blood diseases.[@R7] In the present case, the patient probably developed nocardiosis due to her immunosuppressive condition, which was linked to colorectal cancer itself and the use of steroid hormones for palliative therapy.

The most abundant fungal cell wall consists of the following: a glucose-linked polysaccharide called β-d-glucan, mannan and chitin on the outside. β-d-glucan is widely present in various pathogenical fungi such as *Candida* spp, *Fusarium* spp, *Aspergillus* spp and *Pneumocystis* spp, which was not observed in the cell wall of zygomycetes. These cell wall structures are fungi-specific.[@R12] Therefore, the β-d-glucan levels are a useful marker for a fungal infection diagnosis and reflect the actual extent of fungal infection. The measurement of the β**-**d**-**glucan levels is based on a reaction with limulus reagent, which contains blood cell extract from horseshoe crab for G factor activation.[@R13]

*Nocardia*'s cell wall is type IV and mainly composed of arabinose, galactose, *meso-*2,6-diaminopimelic acid and mycolic acids.[@R14] β**-**d**-**glucan is not believed to be present in the cell wall of any bacteria, including *Nocardia* spp.[@R15] However, a recent study suggested that the polysaccharides found in the cell walls of *Nocardia* spp trigger the limulus reaction. Sawai *et al* reported high levels of serum β**-**d**-**glucan in patients with disseminated *N. farcinica* infection.[@R2] Koncan *et al* found that the culture solutions of *N. neocaledoniensis*, *N. abscessus* and *N. cyriacigeorgica* showed positive results on the β**-**d**-**glucan assay.[@R3] Additionally, refer to Yoneda's description in the patent application publication (US8822163B2), if it is a polysaccharide comprising β-glucan as a constituent, it is likely that β-d-glucan levels elevate. Certain bacteria, such as *Actinomyces, Nocardia*, fungi and mushrooms containing natural polysaccharides in the cell wall, which may even contain β**-**glucan depending on the species.[@R16] The elevated serum β-d-glucan level might be due to cross-reactivity.

Furthermore, *Nocardia* infection is often accompanied by other pathogens, which often show increased β-glucan levels. *Aspergillus* and *Mycobacteria* are the most common agents present in cases of mixed infection.[@R7] Because of cavitary lesion involving elevation of serum β**-**d**-**glucan levels, we considered the possibility of an *Aspergillus* infection in the present case. We were unable to confirm a fungal infection from a respiratory sample. It is difficult to prove *Aspergillus* spp from the respiratory sample microbiologically.[@R17] In this case, we treated pulmonary nocardiosis, concerned about the possibilities of *Aspergillus* infection without use of antifungal agent.

There have been previous reports of some antibiotics interacting with β-d-glucan.[@R8] In the present case, the high levels of β**-**[d]{.smallcaps}**-**glucan were detected before treatment with the β-lactam antibiotic (IPM/CS) and TMP/SMX. No other antibiotic treatment was administered prior to the admission. In the vast majority of cases, nocardiosis develops in patients with a poor physical condition following who have an immunodeficient condition. Before the definitive diagnosis of nocardiosis, treatments which can lead to false positives, for example, TMP/SMX, antifungal agents or immunoglobulins/albumins are often administered.[@R9]

###### Patient's perspective

At the start of her disease course, my mother lost hope and was heartbroken because of her advanced colorectal cancer. She prepared herself for potential pain from the cancer and her eventual death. Therefore, we were surprised to receive the diagnosis of remediable pneumonia. While it was painful to place her under quarantine for a week to avoid mycobacterial infection, we were subsequently able to spend another 3 months with her until she passed away.

###### Learning points

-   The differential diagnoses of radiological cavitary lesions should consider various infections or non-infectious diseases (eg, pulmonary tuberculosis, non-tuberculous mycobacteria, or fungi, vasculitis syndrome and primary and metastatic malignancies).

-   To recognise the risk of infectious disease development (eg, *Candida* spp, *Fusarium* spp, *Aspergillus* spp and *Pneumocystis* spp), β**-**d**-**glucan levels should be carefully observed.

-   *Nocardia* infections may elevate β**-**d**-**glucan levels.

-   Most false-positive reactions of β**-**d**-**glucan assays are attributed to the use of trimethoprim/sulfamethoxazole, antifungal agents or immunoglobulin/albumin preparations haemodialysis.
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